Actinium Announces NIH Grant Extension to Advance Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals has announced an extension of its NIH grant to advance the development of its next-generation CD45 targeted conditioning agent, Iomab-ACT, in collaboration with Memorial Sloan Kettering's CAR-T cell therapy.
October 04, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The NIH grant extension for Actinium Pharmaceuticals will support the development of Iomab-ACT, potentially leading to advancements in CAR-T cell therapy. This could positively impact the company's stock in the short term.
The extension of the NIH grant indicates confidence in Actinium's ongoing research and development efforts. This could lead to positive investor sentiment, potentially driving up the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100